Mixed phenotype acute leukemia is a rare acute leukemia in which blast cells express markers of more than one lineage, typically myeloid and B- or T-lymphoid. It is considered biologically complex and generally high risk.
West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.
A Phase II trial led by WVU Cancer Institute reports the first-ever use of subcutaneous blinatumomab in CD19-positive mixed phenotype acute leukemia, with the first patient achieving complete remission after one cycle.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07498465 |
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia |
WITHDRAWN | PHASE1 |
| NCT07356154 |
A Study of Revumenib and Mezigdomide in People With Leukemia |
RECRUITING | PHASE1/PHASE2 |
| NCT07346105 |
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies |
TEMPORARILY_NOT_AVAILABLE | |
| NCT07256210 |
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation |
RECRUITING | PHASE2 |
| NCT07216443 |
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome |
RECRUITING | PHASE2 |
| NCT06928662 |
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse |
RECRUITING | PHASE1/PHASE2 |
| NCT06551584 |
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT |
RECRUITING | PHASE1 |
| NCT06533579 |
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) |
RECRUITING | PHASE1/PHASE2 |
| NCT06390319 |
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) |
RECRUITING | PHASE2 |
| NCT06289673 |
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma |
RECRUITING | PHASE4 |
